A differential pharmacokinetic analysis of the erythropoietin receptor population in newborn and adult sheep

Journal of Pharmacology and Experimental Therapeutics

Volumn 306, Issue 2, 2003, Pages 532-537

  Veng Pedersen, Peter ^a   Chapel, S ^c   Al Huniti, N H ^a   Schmidt, R L ^b   Sedars, E M ^b   Hohl, R J ^b   Widness, J A ^b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; RECOMBINANT ERYTHROPOIETIN;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG ELIMINATION; ERYTHROID PRECURSOR CELL; HEMATOPOIESIS; HYPOTHESIS; HYPOXEMIA; ISCHEMIA; MICHAELIS CONSTANT; NEUROPROTECTION; NEWBORN; NEWBORN HYPOXIA; NONHUMAN; NONLINEAR SYSTEM; PERINATAL MORBIDITY; POPULATION RESEARCH; PRIORITY JOURNAL; RECEPTOR DENSITY; STATISTICAL SIGNIFICANCE; TRACER INTERACTION METHOD;

ALKYLATING AGENTS; ANIMALS; ANIMALS, NEWBORN; BUSULFAN; KINETICS; METABOLIC CLEARANCE RATE; RECEPTORS, ERYTHROPOIETIN; SHEEP;

EID: 0037960982     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: 10.1124/jpet.103.052431     Document Type: Article

References (34)

1. Carlini RG, Alonzo EJ, Dominguez J, Blanca I, Weisinger JR, Rothstein M, and Bellorin-Font E (1999) Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 55:546-553.
2. Cazzola M, Guarnone R, Cerani P, Centenara E, Rovati A, and Beguin Y (1998) Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood 91:2139-2145.
3. Chapel SH, Veng-Pedersen P, Hohl RJ, Schmidt RL, McGuire EM, and Widnes JA (2001) Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway. J Pharmacol Exp Ther 298:820-827.
4. Clapp DW, Freie B, Lee WH, and Zhang YY (1995) Molecular evidence that in situ-transduced fetal liver hematopoietic stem/progenitor cells give rise to medullary hematopoiesis in adult rats. Blood 86:2113-2122.
5. Davies SV, Fegan CD, Kendall R, Beguin Y, and Cavill I (1995) Serum erythropoietin during autologous bone marrow transplantation: relationship to measures of erythroid activity. Clin Lab Haematol 17:139-144.
6. Dawes GS (1968) Birth Asphyxia Ressucitation and Brain Damage. Year Book Medical Publisher Inc., Chicago.
7. Fisher JW (2003) Erythropoietin: physiology and pharmacology update. Exp Biol Med 224:1-14.
8. Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD, and Vlasses PH (1990) Pharmacokineties and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 47:557-564.
9. Gammeltoft S (1991) Receptor-mediated endocytosis and degradation of polypeptide hormones, growth factors and neuropeptides, in Degradation of Bioactive Substances: Physiology and Pathophysiology (Henriksen JH) pp 140-165, chapter 5, CRC Press, Boston.
10. Grace RJ, Kendall RG, Chapman C, Hartley AE, Barnard DL, and Norfolk DR (1991) Changes in serum erythropoietin levels during allogeneic bone marrow transplantation. Eur J Haematol 47:81-85.
11. Hutchinson MF and deHoog FR (1985) Smoothing noise data with spline functions. Numer Math 47:99-106.
12. Juul S (2002) Erythropoietin in the central nervous system and its use to prevent hypoxic-ischemic brain damage. Acta Paediatr Suppl 438:36-42.
13. Juul SE, Ledbetter DJ, Joyce AE, Dame C, Christensen RD, Zhao Y, and DeMarco V (2001) Erythropoietin acts as a trophic factor in neonatal rat intestine. Gut 49:182-189.
14. Juul SE, Yachnis AT, and Christensen RD (1998) Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 52:235-249.
15. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, and Sugiyama Y (1997a) Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther 283:520-527.
16. Kato M, Kato Y, and Sugiyama Y (1997b) Mechanism of the upregulation of erythropoietin-induced uptake clearance by the spleen. J Pharmacol Exp Ther 283:520-527.
17. Kato M, Miura K, Kamiyama H, Okazaki A, Kumaki K, Kato Y, and Sugiyama Y (1998) Pharmacokinetics of erythropoietin in genetically anemic mice. Drug Metab Dispos 26:126-131.
18. Kendall RG, Chapman C, Hartley AE, and Norfolk DR (1991) Storage and preparation of samples for erythropoietin radioimmunoassay. Clin Lab Haematol 13:189-196.
19. Nagai A, Nakagawa E, Choi HB, Hatori K, Kobayashi S, and Kim SU (2001) Erythropoietin and erythropoietin receptors in human CNS neurons, astrocytes, microglia and oligodendrocytes grown in culture. J Neuropathol Exp Neurol 60:386-392.
20. Potter CG, Potter AC, Hatton CSR, Chapel HM, Anderson MJ, Pattison JR, Tyrrell DAJ, Higgins PG, Willman JS, Parry HF, et al. (1987) Variation of erythroid and myeloid precursors in the marrow and peripheral blood of volunteer subjects infected with human parvovirus (B19). J Clin Investig 79:1486-1492.
21. Sawada K, Krantz SB, Dai CH, Koury ST, Horn ST, Glick AD, and Civin CI (1990) Purification of human blood burst-forming units-erythroid and demonstration of the evolution of erythropoietin receptors. J Cell Physiol 142:219-230.
22. Sawyer ST (1990) Receptors for Erythropoietin. Distribution, Structure and Role in Receptor-Mediated Endocytosis in Erythroid Cells, Plenum Press, New York.
23. Sawyer ST and Hankins WD (1993) The functional form of the erythropoietin receptor is a 78-kDa protein: correlation with cell surface expression, endocytosis and phosphorylation. Proc Natl Acad Sci USA 90:6849-6853.
24. Stohlman F (1959) Observations on the physiology of erythropoietin and its role in the regulation of red cell production. Ann NY Acad Sci 77:710-724.
25. Veng-Pedersen P (1977) Curve fitting and modelling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT. J Pharmacokinet Biopharm 5:513-531.
26. Veng-Pedersen P, Widness JA, Pereira LM, Peters C, Schmidt RL, and Lowe LS (1995) Kinetic evaluation of nonlinear drug elimination by a disposition decomposition analysis. Application to the analysis of the nonlinear elimination kinetics of erythropoietin in adult humans. J Pharm Sci 84:760-767.
27. Veng-Pedersen P, Widness JA, Pereira LM, Schmidt RL, and Lowe LS (1999) A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans. Biopharm Drug Dispos 20:217-223.
28. Veng-Pedersen P, Widness JA, Wang J, and Schmidt RL (1997) A tracer interaction method for nonlinear pharmacokinetics analysis: application to evaluation of nonlinear elimination. J Pharmacokin Biopharm 25:569-593.
29. Widness JA, Clemons GK, Garcia JF, Oh W, and Schwartz R (1984) Increased immunoreactive erythropoietin in cord serum after labor. Am J Obstet Gynecol 148:194-197.
30. Widness JA, Garcia JF, Clemons GK, Cavalieri RL, Susa JB, Teramo KA, and Schwartz R (1986) Temporal response of immunoreactive erythropoietin to acute hypoxemia in the sheep fetus. Pediatr Res 20:15-19.
31. Widness JA, Schmidt RL, Veng-Pedersen P, Modi N, and Sawyer ST (1992a) A sensitive and specific erythropoietin immunoprecipitation assay: application to pharmacokinetic studies. J Lab Clin Med 119:285-294.
32. Widness JA, Veng-Pedersen P, Modi NB, Pereira LM, Schmidt RL, and Lowe LS (1992b) Erythropoietin nonlinear pharmacokinetics in newborn lambs (Abstract). Exp Hematol 20:778.
33. 125I-erythropoietin pharmacokinetics are unchanged after anesthesia, nephrectomy and hepatectomy in sheep. J Pharmacol Exp Ther 279:1205-1210.
34. Yoon WH, Park SJ, Kim IC, and Lee MG (1997) Pharmacokinetics of recombinant human erythropoietin in rabbits and 3/4 nephrectomized rats. Res Commun Mol Pathol Pharmacol 96:227-240.